UBS Global Healthcare Conference - CLOVER HEALTH INVESTMENTS CORP

Explicit Guidance:

• FY2027 Earnings & Growth: Projecting strong momentum continuing into 2027, driven by the maturation of two large cohorts simultaneously (transitioning from year 1 to year 2/3), which is expected to create a "significant tailwind to earnings expansion."
• FY2028 Outlook: Anticipating a potential inflection point where three large cohorts may mature simultaneously in 2028, assuming strong growth continues in 2027, leading to further substantial margin expansion.
• Star Ratings Economics: Confirmed expectation to receive payment economics for a 4.5-star rating in 2027, with similar economics trending into 2028, enabling competitive plan designs and high retention rates.
• Membership Growth: Foreseeing another "strong year of growth" in 2027, building on ~50% market-leading growth rates in 2025 and 2026.
• Capital & Cash Flow: Balance sheet remains strong with > $500 million in cash/securities and zero debt; delivered > $200 million in operating cash flow in 2026, positioning the company to fund regulatory capital needs and continued growth.
• No Long-Term Margin Target: Management explicitly states no long-term margin target is being set until growth rates stabilize, as current high-growth dynamics differ from mature peers; expects margin expansion via cohort maturation but avoids specific percentage guidance.

Business-Segment Outlook:

• 2027 Membership Dynamics: Expecting a significant influx of ~40,000 members in New Jersey displaced by a large competitor's plan exit in the 2027 AEP, projected to represent the majority of new switchers (potentially >85%, matching 2026 levels).
• Medical Trend: Trends are favorable relative to年初 expectations. Inpatient utilization is trending lower (especially for new cohorts) compared to prior year-one cohorts; Part D trends are lighter than expected in 2026 relative to 2025 high levels in the non-low-income population.
• Offsetting Utilization Risks: While inpatient is down, there is an observed shift toward higher outpatient utilization (surgery, observation, ER stays), which is being monitored.
• PPO vs. HMO: Anticipating continued retreat from $0 PPOs by national MCOs, which strengthens Clover's competitive advantage as competitors shift back to HMO/value-based playbooks; Clover expects PPO market advantage to grow.
• Five-Star Contract Impact: Leveraging the 5-star rating to drive incremental enrollments via the Special Enrollment Period (SEP) from April to December, creating an additional growth channel beyond the standard AEP.
• C-SNP Exploration: Viewing Chronic-Condition SNPs (C-SNPs) as a "interesting product type" to consider entering in 2028 and beyond, aligning with Clover Assistant's focus on chronic disease management, though no immediate entry planned for 2027.
• D-SNP Strategy: No plans to become a Medicaid MCO in the near term, precluding entry into fully integrated D-SNP markets (like NJ); D-SNPs remain off-limits unless regulatory structures change.

Market and Competitive Outlook:

• Market Share Shifts: Competitive positioning is strong; new dynamics in 2027 (competitor exits) are expected to provide share gains, though product competitiveness remains the primary driver.
• Pricing Assumptions: 2027 bid trends are expected to be slightly lighter than national peers on an aggregate basis due to the high weighting of lower-cost new member cohorts (years 1-3), though per-factor trends are comparable to peers.
• Switcher Economics: Switchers from other Medicare Advantage plans consistently demonstrate significantly better Medical Loss Ratios (MLRs) than age-in or FFS switchers; these cohorts are a primary growth driver.
• Competitive Landscape: The retreat of large national plans from $0 PPOs is viewed as a structural advantage for Clover, allowing it to maintain premium product positioning while competitors revert to traditional HMO models.

Macro / Industry Outlook:

• Risk Adjustment (V28): Management views the V28 risk adjustment changes as a stress test that Clover navigated successfully (doubling membership and expanding margins while competitors exited or reduced benefits) due to the agility of the Clover Assistant technology.
• Part D Management: The transition to OptumRx (completed ahead of 2027) is aimed at managing Part D costs and Star Ratings more actively, with a focus on medication adherence measures and star rating optimization.
• State Expansion: Expansion into new states will be highly selective and data-driven; specific mention of avoiding "heavily capitated markets" like South Florida that do not fit the non-value-based player model.
• Regulatory Capital: Company feels well-positioned to handle capital needs in February 2027 due to strong cash flow and liquidity.

Strategic Initiatives:

• Clover Assistant Expansion: Prioritizing "double down" efforts on Clover Assistant coverage to drive medical savings and cohort maturation. Extending the technology beyond the point-of-visit to ensure "next best actions" (referrals, meds) are completed.
• Counterpart Health: Near-term goal to manage third-party lives on the Counterpart platform equal to the volume Clover Assistant manages internally; currently on track, focusing on engagement and proof of concept in new markets before scaling economics.
• AI in Operations: Identifying low-hanging fruit for AI to reduce SG&A and operational costs in claims adjudication, provider payment integrity, and member services, given the industry's pre-AI legacy systems.
• Provider Network: Utilizing Counterpart Health partnerships to gain "boots on the ground" market intelligence to identify geographies where Clover Assistant can scale quickly via network physician engagement.
• Clinical Operations Scaling: Preparing to scale clinical operations in 2027 to support the influx of new members and ensure Clover Assistant coverage keeps pace with enrollment.

Risks and Headwinds to Outlook:

• Clover Assistant Coverage: Identified as the primary risk factor for 2027; failure to scale coverage sufficiently for the new member cohort could impair cohort maturation and earnings expansion.
• Network Density: Entering new markets presents a constraint: achieving sufficient provider panel density to drive workflow changes for network physicians may be difficult in the near term compared to the employed clinician model.
• Star Rating Headwinds: While 4.5 stars are secured, management notes that maintaining this requires high retention; any degradation in ratings could impact competitiveness.
• Cost Management: Continued focus needed on provider payment integrity and operations to meet increasing billing intensity.
• External Risks: Potential changes to risk adjustment or Part D measures remain industry-wide variables, though Clover believes its technology provides a faster reaction mechanism than peers.

Management Tone on the Future:

• High Confidence: Tone is "very encouraging" and "confident," citing the "third go-round" of successful growth cycles (2024-2025, 2025-2026, 2026-2027) and the proven engine for managing growth.
• Differentiation: Strong belief that the company can sustain growth and margins without a long-term margin target or Star bonus, provided cohort maturation continues to drive cost efficiencies.
• Strategic Clarity: Clear distinction made between Clover's growth trajectory (scaling cohort value) versus peer models that rely on Star payments; management feels "equally capable" of competing even in a normalized Star environment.
• Cautious Optimism on Expansion: While confident in the core model, expansion plans are described as "granular" and "data-informed," explicitly ruling out rapid, undifferentiated geographic growth (e.g., South Florida).

Miscellaneous:

• PBM Transition: Switch from Caremark to OptumRx was driven by an RFP process seeking a partner to jointly manage costs and Star performance; Optum was the clear winner for the 2027 business.
• Cash Position: Reiteration of financial strength with > $500M cash/securities and $0 debt.
• SG&A Efficiency: Anticipates spreading a fixed cost base (currently ~160k MA lives) over a significantly larger revenue base in 2027-2028 to improve efficiency.